Drug Trial Radar · NCT06447480
Clinical Trial to Compare Oral Isotretinoin to Standard of Care in Moderate Acne Skin of Color Patients
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
420
Planned (sponsor's estimate)
Start
Apr 29, 2025
Primary completion
Sep 1, 2027
Study completion Sep 1, 2028
Sponsor
- Lead sponsor
- Centre Hospitalier Universitaire de NiceAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 13 years, up to 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In Dermatology, assessment of people of color remains underrepresented in RCTs (\<10%) and guidelines. Acne affects around 9% of the population worldwide and negatively affects quality of life and self-esteem with anxiety, suicidal ideation and physical scarring. Main lesions associate comedons, inflammatory papules and pustules which grading of severity allows decision-making, e.g., topicals in mild acne and isotretinoin in severe acne. In darker skin type patients, i.e., Fitzpatrick phototypes IV-VI, acne-related pigmentation (ARP) occurs in 65% of cases which reflects either per- or post-inflammatory hyperpigmentation. Whatever is the mechanism, ARP (number, size, importance of dyschromia) impacts the quality of life in such patients. In moderate acne, treatment is based on oral antibiotics for 3 months, i.e., doxycycline or lymecycline, with topical treatment like tretinoin targeting comedons (and potentially ARP). However, oral antibiotics first-line were developed in white skin patients only and never showed its efficacy in ARP. Moreover, doxycycline could be associated with new-onset hyperpigmentation in acne patients. Isotretinoin -acting on the sebaceous gland and therefore the most effective drug in acne- is only prescribed after failure of antibiotics according to the guidelines.The main objective: To assess the superiority at M6 of a treatment of moderate facial acne in skin of color patients with oral isotretinoin in first line compared to the current standard of care on the severity of ARP.Multicenter randomized controlled trial - open study. The number of subjects required for the trial = 420
Conditions
- Acne Vulgaris
Interventions
ISOtretinoin 5 MGDrug
The dose is usually of 0.5 mg/kg/d. If tolerance is poor, the dose of isotretinoin can be decreased to 0.25 mg/kg/d. After 3 months of treatment, a clinical evaluation is performed. The dose of isotretinoin can be increased up to 1 mg/kg/d depending on the efficacy (ECLA graded as moderated or severe) and tolerance. A total cumulative dose between 120 to 150 mg/kg is recommended.
Topical creamDrug
Topical retinoic acid (Effederm®) or adapalene cream (Differine®), associated during the 3 first months with doxycycline or lymecycline 100 mg/d. After 3 months, the efficacy is assessed. If acne improved, oral antibiotics are stopped and only the topical treatment is continued. If the ECLA is graded as moderated or severe, isotretinoin should be introduced.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Severity of score acne-related pigmentationTime frame: at 6 months
Locations
19 sites in 2 countries. Site status is shown where the registry gives one.
CH D'argenteuil
Argenteuil, France · Recruiting
Cabinet Dermatologique Brest 1
Brest, France · Recruiting
Cabinet Dermatologique Brest 2
Brest, France · Recruiting
Cabinet dermatologique Cenon
Cenon, France · Not yet recruiting
Cabinet dermatologique gradignan
Gradignan, France · Recruiting
CHU de la réunion
La Réunion, France · Recruiting
Ambroise paré
Paris, France · Recruiting
Cabinet dermatologique privé
Paris, France · Not yet recruiting
Cabinet dermatologique
Paris, France · Recruiting
CH Avicenne - APHP
Paris, France · Recruiting
CHU de Poitiers
Poitiers, France · Recruiting
CHU de Nice - Hôpital de l'Archet
Nice, Alpes-Maritimes, France · Recruiting
CHU de Bordeaux
Bordeaux, Aquitaine, France · Recruiting
APHP
Paris, Île-de-France Region, France · Recruiting
CHU de Nantes
Nantes, Loire-Atlantique, France · Recruiting
chu de Rouen
Rouen, Seine-maritime, France · Recruiting
Cabinet de dermatologie St Maxime
Sainte-Maxime, Var, France · Recruiting
CH de Cayenne 3 Avenue Alexis Blaise, BP6006
Cayenne, French Guiana · Recruiting
Cabinet de dermatologie DERMACLINIC 972
Fort-de France, French Guiana · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.